ProQR Therapeutics NV (NASDAQ: PRQR) shares rocketed higher in the pre-market session as the company announced its QR-010 Cystic Fibrosis treatment met its primary endpoint during its Phase 1b study.
Following four weeks of treatment, the study showed that QR-010 restored cystic fibrosis transmembrane conductance regulator function in cystic fibrosis patients.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The company is presenting preliminary data from the Phase 1b study at the North American Cystic Fibrosis Conference today.
Shares of ProQr were higher by $2.40, or 38 percent, to $8.65.